Highlights
- RAD has secured a spot at B. Riley Securities Event for radiopharmaceutical advancements.
- The event will feature over 15 small-to-mid cap public and private companies from the CDMO, industrial, biotech, medtech, and medical services space.
Radiopharm Theranostics (ASX:RAD) is excited to announce its invitation to participate in the B. Riley Securities Radiopharma Investor Conference on 1 March 2024. This event is scheduled to take place in New York.
Over 15 public and private companies (small-to-mid cap) focused on introducing life-saving radiotherapeutics and imaging agents to the market will participate in the event. These companies are from the medtech, medical services, biotech, CDMO (contract development & manufacturing organization), and industrial space.
During the conference, Radiopharm's management will deliver an exclusive presentation about the company, and they will also participate in a panel discussion addressing imaging in radiopharmaceuticals. This opportunity allows them to engage with various institutional and professional investors from the United States, providing valuable insights into the company's advancements and contributions to the field.
RAD is a clinical-stage biopharmaceutical company dedicated to advancing innovative radiopharmaceuticals in areas with significant medical needs.
RAD shares traded at AU$0.058 on 22 February 2024.